Compare Nomura Holdings Inc (NMR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Sanofi SA — how do they compare? Nomura Holdings Inc trades at $9.8 (market cap $28.69B), while Sanofi SA trades at $43.6 (market cap $104.57B). The key difference: Sanofi SA is far larger — about 3.6× Nomura Holdings Inc's market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.
| NMR | SNY | |
|---|---|---|
Market Cap | $28.69B | $104.57B |
Sector | Financials | Health |
52-Week High | $10.04 | $52.34 |
52-Week Low | $6.73 | $41.33 |
Dividend Yield | 3.3% | 5.56% |
Enterprise Value | — | $124.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nomura Holdings (NMR) trades at $9.95, up 0.3% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 11.77 and net income margin of 20.4%, supported by record annual profit in 2025. Recent Q2 2026 earnings beat expectations, and revenue growth trends upward, though cash flow from operations remains negative.
Outlook is positive with valuation appeal and earnings momentum, but risks include volatile cash flows, high debt levels, and reliance on wholesale revenue. Analysts are mixed, with 33% buy ratings. The stock presents a value opportunity amid bullish technicals, yet investors should weigh debt concerns against growth prospects.
SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.
SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
